Effective management of acute migraine requires rapidly aborting pain, restoring functional capacity, and minimizing medication overuse. Historical practices like trepanation or unmonitored ergot use have given way to targeted pharmacotherapies. Today, clinicians use structured care strategies combining non-specific analgesics, antiemetics, ergot derivatives, and 5-HT$_{1\text{B}/1\text{D}}$ receptor agonists (triptans) to treat acute attacks effectively.
General Principles and Delivery Strategies
Optimal acute management depends on timing, route of administration, and treatment structure:
Treat Early: Acute therapies should be administered at the earliest sign of headache for maximum efficacy, before central sensitization develops.
Stratified Care vs. Step Care:
Step Care: Starts all patients on simple analgesics and escalates to migraine-specific therapies only after first-line treatment fails.
Stratified Care: Tailors initial treatment to attack severity. Mild attacks receive non-specific agents, while moderate-to-severe attacks receive immediate migraine-specific therapy (e.g., triptans). Stratified care has Class I evidence supporting superior efficacy and cost-effectiveness.
Non-Oral Routes: Non-oral formulations (nasal sprays, subcutaneous injections, or rectal suppositories) should be used for patients with early severe nausea or vomiting.
Preventing Medication Overuse Headache (MOH): Acute therapies should be restricted to no more than two headache days per week to avoid paradoxical chronic daily headaches.
Non-Specific Acute Therapies
Non-specific agents are primary options for mild-to-moderate attacks:
| Drug Class | Specific Agents & Recommendations | Evidence Grade & Comments |
| NSAIDs & Analgesics | Ibuprofen, Naproxen Sodium, Diclofenac, Aspirin. Acetaminophen alone is not recommended due to low efficacy. | Grade A: Highly effective for mild-to-moderate attacks. Grade B: Acetaminophen monotherapy. |
| Antiemetics & DA Agonists | Metoclopramide, Prochlorperazine, Chlorpromazine. | Grade C: Relieves nausea, improves gastric motility, and enhances oral analgesic absorption. |
| Opioids & Narcotics | Codeine, Meperidine, Morphine combinations. | Grade A (efficacy): Discouraged for routine use due to risks of dependence, sedation, and high MOH potential. |
| Corticosteroids | IV Dexamethasone or Hydrocortisone. | Grade C: Used primarily as rescue therapy to prevent relapse in status migrainosus. |
Triptans: 5-HT$_{1\text{B}/1\text{D}}$ Agonists
Introduced in 1984 with Sumatriptan, triptans are selective serotonin 5-HT$_{1\text{B}/1\text{D}}$ receptor agonists and represent the standard of care for moderate-to-severe acute migraine.
Vascular 5-HT$_{1\text{B}}$ Agonism: Stimulates 5-HT$_{1\text{B}}$ receptors on smooth muscle cells of cranial and meningeal arteries, directly reversing painful vasodilation.
Presynaptic 5-HT$_{1\text{D}}$ Agonism: Binds presynaptic 5-HT$_{1\text{D}}$ receptors on perivascular trigeminal nerve endings, blocking the release of CGRP and Substance P to prevent neurogenic inflammation.
Central TCC Suppression: Crosses into the brainstem to inhibit second-order pain transmission within the trigeminocervical complex.
Overview of Triptan Options
Sumatriptan: The pioneer triptan; available in oral, nasal spray, and subcutaneous formulations (rapid onset).
Second-Generation Triptans: Zolmitriptan, Rizatriptan, Eletriptan, Naratriptan, Frovatriptan, and Almotriptan.
Rizatriptan & Eletriptan: Feature rapid oral absorption and high clinical response rates.
Naratriptan & Frovatriptan: Possess longer half-lives, offering lower recurrence rates and suitability for short-term prevention.
Common Triptan Side Effects
Chest tightness or pressure (non-cardiac "triptan sensations"), flushing, tingling, dizziness, somnolence, and local injection-site reactions.
Ergot Alkaloids and Derivatives
Ergotamine tartrate and its semi-synthetic derivative, dihydroergotamine (DHE), were the first specific acute migraine treatments:
Mechanism: Act as non-selective agonists at 5-HT$_{1\text{B}/1\text{D}/1\text{F}}$, dopaminergic, and $\alpha$-adrenergic receptors, producing potent cranial vasoconstriction and central pain inhibition.
DHE Advantages: DHE exhibits greater $\alpha$-adrenergic antagonism with fewer emetic and vasoconstrictive side effects compared to ergotamine tartrate, making it a valuable option for refractory migraine or status migrainosus.
Adverse Effects & Risks: Nausea, vomiting, abdominal pain, peripheral vasospasm (ergotism), and rebound headache. Contraindicated in patients with coronary artery disease, peripheral vascular disease, uncontrolled hypertension, or renal/hepatic impairment.
Conclusion
Modern acute migraine management emphasizes early intervention using a stratified approach. While NSAIDs and antiemetics remain effective for mild attacks, 5-HT$_{1\text{B}/1\text{D}}$ triptans and ergot derivatives serve as primary options for aborting moderate-to-severe attacks before central sensitization develops.